National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (No. 10) (PB 105 of 2015) (Cth)
PB 105 of 2015
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (No. 10)
National Health Act 1953
___________________________________________________________________________
I, Julianne Quaine, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 27 October 2015
JULIANNE QUAINE
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________
1 Name of Instrument
(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (No.10).
(2)This Instrument may also be cited as PB 105 of 2015.
2 Commencement
This Instrument commences on 1 November 2015.
3 Amendments to PB 79 of 2011
Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
Amendments
Schedule 1 Part 1 entry for Docetaxel in the form Solution concentrate for I.V. infusion 140 mg in 7 ml, and brand Oncotaxel 140:
omit from the column headed “Responsible Person”: GN substitute: EA
Schedule 1 Part 1 entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 4 ml, and brand Oncotaxel 80:
omit from the column headed “Responsible Person”: GN substitute: EA
Schedule 1 Part 1 entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial and brand Accord Doxorubicin:
omit from the column headed “Responsible Person”: GN substitute: EA
Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL and brand Irinotecan Actavis 500:
omit from the column headed “Responsible Person”: UA substitute: EA
Schedule 1 Part 1, entry for Paclitaxel in each of the forms: Solution concentrate for I.V infusion 100 mg in 16.7 mL; Solution concentrate for I.V infusion 150 mg in 25 mL; Solution concentrate for I.V infusion 30 mg in 5 mL and Solution concentrate for I.V infusion 300 mg in 50 mL and brand Paclitaxel Actavis:
omit from the column headed “Responsible Person”: UA substitute: EA
Schedule 1 Part 1, entry for Paclitaxel in each of the forms: Solution concentrate for I.V infusion 100 mg in 16.7 mL; Solution concentrate for I.V infusion 150 mg in 25 mL; Solution concentrate for I.V infusion 30 mg in 5 mL; and Solution concentrate for I.V infusion 300 mg in 50 mL and brand Plaxel:
omit from the column headed “Responsible Person”: GN substitute: ED
Schedule 2, entry for Bacillus Calmette and Guerin, Connaught Strain and brand ImmuCyst:
omit from the column headed ‘Circumstances’: C1419
insert in the column headed ‘Circumstances’: C5598
Schedule 2, entry for Bacillus Calmette and Guerin, Tice Strain and brand OncoTICE:
omit from the column headed ‘Circumstances’: C1290
insert in the column headed ‘Circumstances’: C5597
Schedule 4, entry for Bacillus Calmette and Guerin, Connaught Strain and entry for Bacillus Calmette and Guerin, Tice Strain:
omit:
Bacillus Calmette and Guerin, Connaught strain C1419 Treatment of carcinoma in situ of the urinary bladder
Bacillus Calmette and Guerin, Tice strain C1290 Primary and relapsing superficial urothelial carcinoma of the bladder
[10] Schedule 4, after entry for Arsenic:
insert:
Bacillus Calmette and Guerin, Connaught strain C5598 Carcinoma in situ of the urinary bladder
Bacillus Calmette and Guerin, Tice strain C5597 Primary and relapsing superficial urothelial carcinoma of the bladder
0
0
0